Pharmaceutical Investing Vertex Announces Northern Ireland Offer Accepted for Cystic Fibrosis Treatments
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis